While BRG1 treatments have been promising, a more comprehensive understanding of BRG1’s effect on certain cancer pathways may allow for dual treatments consisting of BRG1 inhibition and upregulating/downregulating another pathway involved in cancer proliferation. The gene discussed is SMARCA4; the disease is cancer.